European Union pays $74M to USA drugmaker for COVID-19 treatment

Henrietta Brewer
August 3, 2020

According to a release, Veklury, also known as remdesivir, was created to treat coronavirus in adults and adolescents aged 12 years and older, and weighing at least 40 kg, who have pneumonia requiring supplemental oxygen.

Stella Kyriakides, Commissioner for Health and Food Safety, stated: 'In recent weeks the Commission has been working tirelessly with Gilead to reach an agreement guaranteeing the delivery to the European Union of stocks of the first authorized treatment against Covid -19. The drug manufacturer, Gilead, did not seek to have it authorized for use in pregnant women or children.

Health Canada will allow the conditional use of the drug, remdesivir to treat people suffering from severe symptoms of COVID-19.


The approval comes after an expedited six-week review of the medication, which is already being used in some countries like the U.S., Japan, and Australia.

FILE - In this March 2020 photo provided by Gilead Sciences, rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site in the United States. With the authorization of remdesivir, the program will no longer be required to access the drug.

The drug interferes with the coronavirus's ability to copy its genetic material.


The drug's safety, efficiency in treatment, as well as data from clinical trials, and other data will be monitored and documented.

Stella Kyriakides, Commissioner for Health and Food Safety, said: "In recent weeks, the Commission has been working tirelessly with Gilead to reach an agreement to ensure that stocks of the first treatment authorised against COVID-19 are delivered to the EU". That represents 100% of Gilead's projected production for July and 90% of production for August and September, according to the agency.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER